Company intelligence / Profile preview
SMSbiotech
San Diego, California, USAsmsbiotech.com ↗
- Ownership
- Private
- Employees
- ~13
- Development stage
- Phase 1
01
Overview
SMSbiotech has developed a patented platform based on novel human allogeneic adult Small Mobile Stem Cells. The company’s technology aims to address tissue degeneration underlying chronic and age-related diseases such as COPD, ARDS, and chronic wounds. As of now, the company remains in the pre-clinical stage with no reported clinical trial results.
- Therapeutic areas
- PulmonologyDermatology
- Modalities
- Cell therapy (allogeneic adult stem cells)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Collaborations with scientific institutions and leading research organizations are mentioned but not named specifically.
Beyond the preview
Go deeper on SMSbiotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SMSbiotech.